Firm Retention Summary: Codiak BioSciences Inc.

12mon ago, source: Hosted on MSN

This is a summary of a request from Codiak BioSciences Inc. to hire Young Conaway Stargatt & Taylor LLP as counsel, filed April 7 with the U.S. Bankruptcy Court in Wilmington, Del. COMPANY ...

Codiak BioSciences, Inc. (CDAK) stock forecast and price target

2y ago, source: Yahoo Finance

Find the latest Codiak BioSciences, Inc. CDAK analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.

Codiak BioSciences, Inc. (CDAKQ)

11mon ago, source: Nasdaq

*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past ...

Anne-Virginie Eggimann's Net Worth

1mon ago, source: Benzinga.com

This is based on reported shares across multiple companies, which include bluebird bio, Inc., and Codiak BioSciences, Inc.. Attention insiders: Dive deeper into market movements and stay ahead of ...

CTKB Cytek Biosciences, Inc.

11mon ago, source: Seeking Alpha

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and ...

ASMB Assembly Biosciences, Inc.

4d ago, source: Seeking Alpha

Assembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company’s ...

Aptose Biosciences Inc APTO

1d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Yield10 Bioscience, Inc. (YTEN)

17h ago, source: Yahoo Finance

Yield10 Bioscience, Inc. (NASDAQ:YTEN) Q4 2023 Earnings Call Transcript April 1, 2024 Yield10 Bioscience, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were $-0.11.

ARCH Venture Fund VIII Overage, L.P.'s Net Worth

2mon ago, source: Benzinga.com

Who is ARCH Venture Fund VIII Overage, L.P.? ARCH Venture Fund VIII Overage, L.P. has an estimated net worth of $525 Million. This is based on reported shares across multiple companies, which ...

Aura Biosciences Inc AURA

2d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Forte Biosciences Inc.

9mon ago, source: CNN

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The firm's lead product includes FB-401, which is a live biotherapeutic ...